Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Non-Current Deffered Revenue: 2020-2022

Historic Non-Current Deffered Revenue for Janux Therapeutics (JANX) over the last 3 years, with Dec 2022 value amounting to $2.2 million.

  • Janux Therapeutics' Non-Current Deffered Revenue fell 94.20% to $307,000 in Q2 2023 from the same period last year, while for Jun 2023 it was $307,000, marking a year-over-year decrease of 94.20%. This contributed to the annual value of $2.2 million for FY2022, which is 217.29% up from last year.
  • As of FY2022, Janux Therapeutics' Non-Current Deffered Revenue stood at $2.2 million, which was up 217.29% from $700,000 recorded in FY2021.
  • Janux Therapeutics' Non-Current Deffered Revenue's 5-year high stood at $6.0 million during FY2020, with a 5-year trough of $700,000 in FY2021.
  • Moreover, its 3-year median value for Non-Current Deffered Revenue was $2.2 million (2022), whereas its average is $3.0 million.
  • Per our database at Business Quant, Janux Therapeutics' Non-Current Deffered Revenue crashed by 88.43% in 2021 and then skyrocketed by 217.29% in 2022.
  • Over the past 3 years, Janux Therapeutics' Non-Current Deffered Revenue (Yearly) stood at $6.0 million in 2020, then slumped by 88.43% to $700,000 in 2021, then surged by 217.29% to $2.2 million in 2022.